Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03173053
Other study ID # NL 61885.091.17
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date February 8, 2018
Est. completion date October 14, 2021

Study information

Verified date October 2020
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial focusses on identifying the most effective and safe long-term S. aureus carriage decolonization strategy in home parenteral nutrition patients. Half of the participants will receive a quick and short systemic antibiotic treatment combined with topical treatment, while the other half will receive only topical treatment on a periodic basis.


Description:

Patients on home parenteral nutrition (HPN) are exposed to a lifelong risk of developing S. aureus bacteremia (SAB). SAB pose a threat to both catheter and patient survival and may lead to a permanent loss of vascular access. S. aureus carriage eradication has proven successful in prevention of S. aureus infections. S. aureus decolonization is a key strategy to maintain venous access and avoid hospitalization.


Recruitment information / eligibility

Status Terminated
Enrollment 63
Est. completion date October 14, 2021
Est. primary completion date October 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is fully able to understand the nature of the proposed intervention. - Written informed consent by the patient before entering the trial. - Age = 18 years. - Estimated life expectancy = 1 year. - Patient colonized with S. aureus. Exclusion Criteria: - Cannot be expected to comply with the trial plan (substance abuse, mental condition). - Pregnant or breastfeeding women. - Continuous exposure to Methicillin-resistant S. aureus (MRSA; e.g. pig farmer). - Allergy for chlorhexidine and betadine. - No options for oral and/or topical antibiotics due to allergies. - Active S. aureus infection. - Currently on treatment with antibiotics active against S. aureus. - Decolonization (including mupirocin) treatment in the previous two months. - The presence of a nasal foreign body. - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels more than five times the upper limit of normal or liver failure.

Study Design


Intervention

Drug:
Doxycycline
tablet
Trimethoprim
tablet
Sulfamethoxazole/trimethoprim
tablet
Clindamycin
tablet
Clarithromycin
tablet
Ciprofloxacin
tablet
Fusidic Acid
tablet or ointment
Rifampin
tablet
Chlorhexidine
Mouthwash or bodywash
Mupirocin
Nasal ointment
Betadine
Shampoo

Locations

Country Name City State
Denmark Aalborg Universitetshospital Aalborg
Denmark Rigshospitalet Copenhagen
Netherlands AMC Amsterdam Noord-Holland
Netherlands Radboud UMC Nijmegen Gelderland

Sponsors (4)

Lead Sponsor Collaborator
Radboud University Medical Center Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University College, London, ZonMw: The Netherlands Organisation for Health Research and Development

Countries where clinical trial is conducted

Denmark,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients totally eradicated for S. aureus during one year Totally eradicated is defined as 100% of all culture swabs (nose, throat, rectum), exit-site catheter and body regions on indication) being negative for S. aureus. One year
Secondary Proportion of patients totally eradicated after one year Proportion of patients totally eradicated for S. aureus based on negative cultures performed after one year One year
Secondary Developing long-term antimicrobial resistance Long-term antimicrobial resistance at 6 and 12 months (measured with standard cultures and NGS) 6 and 12 months
Secondary Incidence of S. aureus infections Incidence of S. aureus infections measured with (serious) adverse events forms every 3 months Every 3 months during one year
Secondary Overall incidence of infections Overall incidence and time to onset of infections measured with (serious) adverse events forms every 3 months Every three months during one year
Secondary Number of catheter removals Number of catheter removals based on data from electronic patient dossier One year
Secondary Mortality Mortality based on data from electronic patient dossier One year
Secondary S. aureus transmission S. aureus transmission routes from caregiver to patient (measured with NGS). One year
Secondary Patient compliance Patient compliance (measured with medication files, counting pills, trial-specific medication diary). Every three months during one year
Secondary Adverse events Adverse events (measured with (serious) adverse event forms every 3 months). Every three months during one year
Secondary Predictors for infections and treatment outcome Predictors for infections and treatment failure/success (binominal regression analysis). One year
Secondary Health related quality of life Generic health related quality of life (measured with a validated questionnaire (EQ5D-5L)). 0, 6 and 12 months
Secondary Healthcare related costs. Cost-effectiveness analysis One year
See also
  Status Clinical Trial Phase
Recruiting NCT05073926 - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Completed NCT01212120 - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections N/A
Completed NCT00801879 - Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection Phase 4
Terminated NCT03638947 - Reducing Perioperative S. Aureus Transmission N/A
Recruiting NCT05331885 - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 Phase 3
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Not yet recruiting NCT05092464 - Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis N/A
Recruiting NCT05695196 - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant Phase 1
Enrolling by invitation NCT04666532 - S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
Active, not recruiting NCT02572791 - Staph Household Intervention for Eradication (SHINE) Phase 4
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT01011335 - Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial Phase 1/Phase 2
Completed NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Not yet recruiting NCT04884958 - A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
Completed NCT01105767 - Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees N/A
Completed NCT00475930 - Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates N/A
Completed NCT00507247 - Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Phase 2
Recruiting NCT03220386 - Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making N/A
Completed NCT03140423 - Mupirocin-Iodophor ICU Decolonization Swap Out Trial Phase 4